
  
    
      
        Background_NNP
        The_DT role_NN of_IN genetics_NNS in_IN modulating_VBG the_DT immune_JJ response_NN
        to_TO infectious_JJ diseases_NNS is_VBZ a_DT topic_NN of_IN longstanding_JJ interest_NN
        among_IN epidemiologists_NNS ,_, clinicians_NNS ,_, population_NN geneticists_NNS ,_,
        and_CC immunologists_NNS [_NN 1_CD 2_CD ]_NN ._. Zinkernagel_NNP and_CC Doherty_NNP 's_POS Nobel_NNP
        Prize-winning_JJ discovery_NN that_IN cellular_JJ immunity_NN to_TO viral_JJ
        infections_NNS was_VBD "_'' restricted_VBN "_'' by_IN the_DT highly_RB variable_JJ proteins_NNS
        of_IN the_DT Major_NNP Histocompatibility_NNP Complex_JJ (_( MHC_NNP )_) brought_VBD the_DT
        field_NN of_IN immunogenetics_NNS into_IN sharper_JJR focus_NN [_NN 3_CD ]_NN ._. Their_PRP$
        demonstration_NN that_IN T_NN lymphocytes_NNS recognize_VBP virus_NN antigens_NNS
        displayed_VBN on_IN a_DT host_NN cell_NN "_'' in_IN the_DT context_NN of_IN "_'' MHC_NNP proteins_NNS
        immediately_RB suggested_VBD the_DT idea_NN that_IN genetic_JJ differences_NNS at_IN
        the_DT loci_NN encoding_VBG the_DT MHC_NNP might_MD modulate_VBP the_DT intensity_NN and_CC
        effectiveness_NN of_IN host_NN response_NN to_TO infection_NN ._.
        The_DT relationship_NN between_IN MHC_NNP genotype_NN and_CC infectious_JJ
        disease_NN resistance_NN can_MD take_VB several_JJ forms_NNS ._. Most_JJS simply_RB ,_,
        individual_JJ MHC_NNP alleles_NNS may_MD be_VB especially_RB effective_JJ ,_, or_CC
        especially_RB ineffective_JJ ,_, at_IN presenting_VBG antigens_NNS from_IN
        particular_JJ infections_NNS ,_, so_IN that_IN carrying_VBG one_CD or_CC two_CD copies_NNS
        of_IN a_DT given_VBN MHC_NNP allele_NN might_MD predispose_VB an_DT infected_JJ
        individual_NN to_TO a_DT more_JJR or_CC less_RBR favorable_JJ disease_NN outcome_NN ._. A_DT
        second_JJ ,_, distinct_JJ but_CC compatible_JJ hypothesis_NNS was_VBD suggested_VBN by_IN
        Doherty_NNP and_CC Zinkernagel_NNP soon_RB after_IN their_PRP$ discovery_NN of_IN MHC_NNP
        restriction_NN :_: since_IN each_DT MHC_NNP allele_NN provides_VBZ an_DT infected_VBN
        individual_NN with_IN the_DT ability_NN to_TO present_VB a_DT particular_RB set_NN of_IN
        antigens_NNS ,_, individuals_NNS who_WP are_VBP heterozygous_JJ (_( say_VBP ,_, genotype_NN
        XY_NNP )_) at_IN a_DT particular_JJ MHC_NNP locus_JJ may_MD mount_VB a_DT more_RBR vigorous_JJ
        immune_JJ response_NN to_TO a_DT given_VBN infection_NN ,_, resulting_VBG in_IN a_DT better_JJR
        outcome_NN ,_, than_IN individuals_NNS who_WP are_VBP homozygous_JJ for_IN either_DT of_IN
        the_DT corresponding_JJ alleles_NNS (_( XX_NNP or_CC YY_NNP )_) [_NN 4_CD ]_NN ._.
        Determining_VBG whether_IN either_DT or_CC both_DT of_IN these_DT mechanisms_NNS
        operates_VBZ for_IN a_DT particular_JJ disease_NN is_VBZ of_IN interest_NN for_IN a_DT
        variety_NN of_IN basic_JJ and_CC applied_VBN purposes_NNS ._. Epidemiologically_NNP ,_,
        HLA_NNP genotype_NN partially_RB accounts_VBZ for_IN inter-patient_JJ variation_NN
        in_IN disease_NN severity_NN or_CC progression_NN rates_NNS for_IN such_JJ long-term_JJ
        viral_JJ infections_NNS as_IN HIV_NNP ,_, human_JJ T-_NNP cell_NN lymphotropic_JJ virus_NN ,_,
        type_NN 1_CD (_( HTLV-_NNP 1_LS )_) ,_, and_CC hepatitis_NNP B_NNP and_CC C_NNP [_NN 5_CD 6_CD 7_CD 8_CD 9_CD ]_NN ._. Such_JJ
        associations_NNS can_MD lead_VB to_TO mechanistic_JJ studies_NNS to_TO test_VB
        hypotheses_NNS about_IN the_DT immunologic_JJ basis_NN of_IN these_DT
        associations_NNS [_NN 10_CD 11_CD ]_NN and_CC could_MD ,_, in_IN principle_NN ,_, be_VB used_VBN to_TO
        help_VB predict_VBP individual_JJ prognoses_NNS [_NN 12_CD 13_CD ]_NN ._. At_IN least_JJS one_CD
        clinical_JJ study_NN has_VBZ shown_VBN that_IN HLA_NNP genotype_NN affects_VBZ the_DT
        immune_JJ response_NN to_TO a_DT candidate_NN HIV_NNP vaccine_NN [_NN 14_CD ]_NN ._. Vaccine_NNP
        designers_NNS have_VBP begun_VBN to_TO take_VB account_NN of_IN the_DT HLA_NNP genotypes_NNS
        of_IN potential_JJ recipients_NNS in_IN choosing_VBG antigens_NNS for_IN inclusion_NN
        in_IN a_DT vaccine_NN [_NN 15_CD ]_NN ,_, and_CC it_PRP has_VBZ been_VBN suggested_VBN that_IN HLA_NNP
        genotype_NN be_VB considered_VBN in_IN designing_VBG samples_NNS for_IN inclusion_NN
        in_IN epidemiologic_JJ studies_NNS of_IN anti-_NN HIV_NNP immune_JJ response_NN [_NN 12_CD ]_NN
        ._. In_IN evolutionary_JJ biology_NN ,_, the_DT possibility_NN that_IN HLA_NNP
        heterozygotes_NNS are_VBP more_RBR resistant_JJ to_TO infectious_JJ diseases_NNS is_VBZ
        the_DT basis_NN for_IN a_DT leading_VBG hypothesis_NNS to_TO explain_VB the_DT
        unparalleled_JJ diversity_NN of_IN HLA_NNP genes_NNS (_( and_CC MHC_NNP genes_NNS in_IN other_JJ
        vertebrates_NNS )_) and_CC the_DT maintenance_NN of_IN this_DT diversity_NN over_IN
        long_JJ periods_NNS of_IN evolutionary_JJ time_NN [_NN 16_CD ]_NN ._.
        Of_IN the_DT two_CD ways_NNS described_VBD above_IN in_IN which_WDT MHC_NNP genotype_NN
        may_MD affect_VB disease_NN outcome_NN ,_, the_DT first_JJ -_: association_NN between_IN
        a_DT particular_JJ allele_NN and_CC disease_NN outcome_NN -_: has_VBZ been_VBN
        repeatedly_RB documented_VBN in_IN human_JJ populations_NNS by_IN various_JJ
        methods_NNS of_IN genetic_JJ epidemiology_NN [_NN 17_CD ]_NN ._. The_DT second_JJ kind_NN of_IN
        effect_NN ,_, more_RBR vigorous_JJ immune_JJ responses_NNS to_TO a_DT pathogen_NN by_IN a_DT
        heterozygote_NN as_IN compared_VBN to_TO homozygotes_NNS for_IN the_DT same_JJ
        alleles_NNS ,_, which_WDT we_PRP term_NN "_'' allele-specific_JJ overdominance_NN ,_, "_'' has_VBZ
        been_VBN suggested_VBN by_IN several_JJ animal_NN studies_NNS [_NN 18_CD 19_CD 20_CD 21_CD ]_NN ,_,
        although_IN none_NN of_IN these_DT studies_NNS is_VBZ unambiguous_JJ (_( see_VB
        DISCUSSION_NNP )_) ._. There_EX have_VBP been_VBN no_DT studies_NNS (_( to_TO our_PRP$ knowledge_NN )_)
        in_IN humans_NNS that_WDT directly_RB compare_VB the_DT infectious_JJ disease_NN
        outcomes_NNS of_IN heterozygotes_NNS to_TO those_DT of_IN homozygotes_NNS for_IN the_DT
        same_JJ alleles_NNS (_( interestingly_RB ,_, the_DT situation_NN is_VBZ very_RB
        different_JJ for_IN autoimmune_JJ diseases_NNS ;_: see_VB DISCUSSION_NNP for_IN
        further_JJ consideration_NN )_) ._.
        As_IN an_DT alternative_NN to_TO directly_RB examining_VBG the_DT hypothesis_NNS
        of_IN allele-specific_JJ overdominance_NN ,_, several_JJ investigators_NNS
        have_VBP compared_VBN the_DT infectious_JJ disease_NN outcomes_NNS of_IN
        heterozygotes_NNS at_IN a_DT given_VBN HLA_NNP locus_JJ ,_, as_IN a_DT group_NN ,_, to_TO the_DT
        outcomes_NNS of_IN homozygotes_NNS at_IN the_DT same_JJ locus_JJ ,_, as_IN a_DT group_NN ._. In_IN
        many_JJ cases_NNS ,_, heterozygotes_NNS as_IN a_DT group_NN have_VBP shown_VBN better_RBR
        infectious_JJ disease_NN outcomes_NNS (_( slower_JJR disease_NN progression_NN or_CC
        more_RBR rapid_JJ clearance_NN of_IN viral_JJ infection_NN )_) than_IN homozygotes_NNS
        as_IN a_DT group_NN [_NN 5_CD 6_CD 8_CD 9_CD 14_CD 22_CD ]_NN ,_, a_DT phenomenon_NN we_PRP call_VBP
        "_'' population_NN heterozygote_NN advantage_NN ._. "_'' Because_IN these_DT studies_NNS
        group_NN all_DT homozygotes_NNS and_CC group_VB all_DT heterozygotes_NNS ,_, they_PRP do_VBP
        not_RB ,_, in_IN fact_NN ,_, test_NN the_DT hypothesis_NNS of_IN allele-specific_JJ
        overdominance_NN ,_, which_WDT is_VBZ conditional_JJ on_IN the_DT alleles_NNS
        involved_VBN ._. Although_IN population_NN heterozygote_NN advantage_NN and_CC
        allele-specific_JJ overdominance_NN are_VBP different_JJ [_NN 10_CD ]_NN ,_,
        reports_NNS of_IN population_NN heterozygote_NN advantage_NN have_VBP
        frequently_RB been_VBN interpreted_VBN as_IN confirmations_NNS of_IN the_DT
        Doherty-_NNP Zinkernagel_NNP hypothesis_NNS of_IN allele-specific_JJ
        overdominance_NN ._.
        In_IN this_DT report_NN ,_, we_PRP show_VBP that_IN although_IN population_NN
        heterozygote_NN advantage_NN is_VBZ compatible_JJ with_IN allele-specific_JJ
        overdominance_NN ,_, it_PRP is_VBZ also_RB compatible_JJ with_IN the_DT opposite_JJ ;_:
        i_NNP ._. e_SYM ._. ,_, population_NN heterozygote_NN advantage_NN could_MD arise_VB in_IN a_DT
        population_NN in_IN which_WDT every_DT heterozygote_NN had_VBD a_DT 
        worse_JJR disease_NN outcome_NN than_IN either_DT of_IN
        the_DT corresponding_JJ homozygotes_NNS (_( "_'' allele-specific_JJ
        underdominance_NN "_'' )_) ._. The_DT reason_NN for_IN this_DT disconnect_VB is_VBZ an_DT
        unusual_JJ form_NN of_IN confounding_VBG in_IN which_WDT particular_JJ (_( protective_JJ
        or_CC detrimental_JJ )_) alleles_NNS are_VBP over-_NN or_CC under-represented_JJ
        among_IN heterozygotes_NNS ,_, as_IN we_PRP discuss_VBP below_IN ;_: an_DT additional_JJ
        factor_NN that_WDT may_MD be_VB involved_VBN results_NNS from_IN the_DT effects_NNS of_IN
        dominance_NN in_IN creating_VBG an_DT asymmetry_NN between_IN homozygotes_NNS and_CC
        heterozygotes_NNS ._. As_IN we_PRP have_VBP suggested_VBN above_IN ,_, it_PRP is_VBZ
        biologically_RB and_CC epidemiologically_RB useful_JJ to_TO determine_VB (_( a_DT )_)
        the_DT beneficial_JJ or_CC harmful_JJ effects_NNS of_IN specific_JJ alleles_NNS ,_, and_CC
        (_( b_SYM )_) the_DT effects_NNS of_IN heterozygosity_NN ,_, such_JJ as_IN allele-specific_JJ
        overdominance_NN ;_: we_PRP show_VBP here_RB that_IN unconditional_JJ comparisons_NNS
        of_IN all_DT heterozygotes_NNS to_TO all_DT homozygotes_NNS can_MD reflect_VB either_CC
        or_CC both_DT of_IN these_DT ,_, and_CC cannot_NN distinguish_VB them_PRP ._. To_TO measure_VB
        the_DT quantitites_NNS of_IN direct_JJ interest_NN ,_, analyses_NNS that_WDT compare_VBP
        disease_NN outcomes_NNS conditional_JJ on_IN the_DT alleles_NNS involved_VBN ,_,
        rather_RB than_IN grouped_VBN comparisons_NNS of_IN heterozygotes_NNS to_TO
        homozygotes_NNS ,_, will_MD be_VB more_RBR informative_JJ ._.
        In_IN the_DT first_JJ section_NN below_IN ,_, we_PRP outline_VB a_DT general_JJ model_NN
        for_IN the_DT relationship_NN between_IN genotype_NN at_IN a_DT particular_JJ HLA_NNP
        locus_JJ and_CC infectious_JJ disease_NN outcome_NN (_( which_WDT we_PRP dichotomize_NN
        into_IN favorable_JJ and_CC unfavorable_JJ )_) ,_, and_CC we_PRP use_VBP the_DT model_NN to_TO
        define_VB the_DT conditions_NNS under_IN which_WDT population_NN heterozygote_NN
        advantage_NN is_VBZ expected_VBN ._. We_PRP show_VBP that_IN ,_, depending_VBG on_IN allele_NN
        frequencies_NNS at_IN the_DT HLA_NNP locus_JJ of_IN interest_NN ,_, population_NN
        heterozygote_NN advantage_NN may_MD occur_VB when_WRB there_EX is_VBZ
        allele-specific_JJ overdominance_NN ,_, but_CC may_MD also_RB occur_VB under_IN
        other_JJ conditions_NNS ,_, including_VBG allele-specific_JJ underdominance_NN ._.
        Two_CD examples_NNS are_VBP given_VBN to_TO illustrate_VB the_DT reasons_NNS for_IN the_DT
        lack_NN of_IN concordance_NN between_IN population_NN and_CC allele-specific_JJ
        effects_NNS ._. In_IN the_DT Discussion_NNP ,_, we_PRP suggest_VBP some_DT possible_JJ
        approaches_NNS for_IN estimating_VBG allele-specific_JJ effects_NNS ._.
      
      
        General_NNP Model_NNP
        To_TO determine_VB the_DT precise_JJ conditions_NNS under_IN which_WDT
        population_NN heterozygote_NN advantage_NN will_MD be_VB observed_VBN ,_, we_PRP
        consider_VBP a_DT general_JJ model_NN that_WDT predicts_VBZ the_DT expected_VBN outcome_NN
        of_IN a_DT comparison_NN between_IN heterozygotes_NNS and_CC homozygotes_NNS in_IN an_DT
        epidemiological_JJ study_NN as_IN a_DT function_NN of_IN (_( i_NNP )_) the_DT frequencies_NNS
        of_IN resistant_JJ and_CC susceptible_JJ alleles_NNS at_IN a_DT particular_JJ locus_JJ
        and_CC (_( ii_NN )_) the_DT relationship_NN between_IN genotype_NN at_IN that_DT locus_JJ
        and_CC phenotype_NN ._. Note_VB that_IN this_DT is_VBZ 
        not_RB a_DT model_NN for_IN the_DT evolution_NN of_IN
        genotype_NN frequencies_NNS or_CC for_IN the_DT maintenance_NN of_IN MHC_NNP
        heterozygosity_NN ,_, but_CC simply_RB an_DT algebraic_JJ framework_NN for_IN
        predicting_VBG the_DT outcome_NN of_IN an_DT epidemiological_JJ study_NN of_IN the_DT
        type_NN cited_VBD above_IN ,_, given_VBN current_JJ allele_NN frequencies_NNS and_CC
        genotype-phenotype_JJ mappings_NNS ._.
        The_DT model_NN is_VBZ summarized_VBD in_IN Table_NNP 1_CD ._. Suppose_VB that_IN
        individual_JJ alleles_NNS of_IN a_DT particular_JJ locus_JJ confer_VB either_CC
        susceptibility_NN or_CC resistance_NN to_TO a_DT given_VBN disease_NN ,_, and_CC that_IN
        there_EX are_VBP 
        m_NN resistance_NN alleles_NNS ,_, 
        R_NN 
        1_CD ,_, 
        R_NN 
        2_CD ,_, ._. ,_, 
        R_NN 
        
          m_NN 
         with_IN frequencies_NNS 
        p_NN 
        1_CD ,_, 
        p_NN 
        2_CD ,_, ._. ,_, 
        p_NN 
        
          m_NN 
         in_IN the_DT population_NN ,_, and_CC 
        n_NN susceptibility_NN alleles_NNS 
        S_NNP 
        1_CD ,_, 
        S_NNP 
        2_CD ,_, ._. ,_, 
        S_NNP 
        
          n_NN 
         with_IN frequencies_NNS 
        q_NN 
        1_CD ,_, 
        q_NN 
        2_CD ,_, ._. ,_, 
        q_NN 
        
          n_NN 
         ._. Let_VB be_VB the_DT total_JJ frequency_NN of_IN resistant_JJ alleles_NNS ,_, and_CC
        be_VB the_DT total_JJ frequency_NN of_IN susceptible_JJ alleles_NNS ,_, with_IN 
        p_NN +_NN 
        q_NN =_SYM 1_CD ._. Further_RB ,_, define_VB and_CC are_VBP the_DT
        sums_NNS of_IN squared_VBN frequencies_NNS of_IN the_DT resistant_JJ and_CC
        susceptible_JJ alleles_NNS ,_, respectively_RB ._. We_PRP assume_VBP Hardy-_NNP Weinberg_NNP
        genotype_NN frequencies_NNS [_NN 23_CD ]_NN throughout_IN ._. Thus_RB ,_, Π_NN is_VBZ the_DT
        frequency_NN of_IN RR_NNP homozygotes_NNS and_CC is_VBZ an_DT inverse_NN measure_NN of_IN
        the_DT diversity_NN of_IN resistant_JJ alleles_NNS ,_, while_IN Θ_NN ,_, the_DT frequency_NN
        of_IN SS_NNP homozygotes_NNS ,_, is_VBZ an_DT inverse_NN measure_NN of_IN the_DT diversity_NN
        of_IN susceptible_JJ alleles_NNS ._.
        We_PRP assume_VBP that_IN SS_NNP homozygotes_NNS have_VBP a_DT probability_NN 
        x_SYM of_IN a_DT favorable_JJ disease_NN course_NN ,_, and_CC
        that_IN SS_NNP heterozygotes_NNS (_( carrying_VBG two_CD different_JJ susceptible_JJ
        alleles_NNS )_) ,_, SR_NNP heterozygotes_NNS ,_, RR_NNP heterozygotes_NNS ,_, and_CC RR_NNP
        homozygotes_NNS have_VBP probabilities_NNS 
        ax_NN ,_, 
        bx_NN ,_, 
        cx_NN ,_, and_CC 
        dx_NN respectively_RB (_( see_VB Table_NNP 1_LS )_) ._. To_TO
        give_VB meaning_VBG to_TO the_DT notions_NNS of_IN resistant_JJ and_CC susceptible_JJ
        alleles_NNS ,_, we_PRP assume_VBP 
        d_SYM >_NN 1_CD (_( RR_NNP homozygotes_NNS do_VBP better_JJR
        than_IN SS_NNP homozygotes_NNS )_) and_CC 
        a_DT ≤_NN 
        b_SYM ≤_NN 
        c_SYM (_( given_VBN that_IN one_CD is_VBZ heterozygous_JJ ,_,
        more_JJR R_NN alleles_NNS are_VBP better_JJR )_) ._. This_DT model_NN can_MD accommodate_VB
        dominance_NN (_( 
        a_DT =_SYM 1_CD ;_: 
        b_SYM =_SYM 
        c_SYM =_SYM 
        d_SYM )_) ,_, additivity_NN (_( 
        a_DT =_SYM 1_CD ;_: 
        c_SYM =_SYM 
        d_SYM ;_: 
        b_SYM =_SYM (_( 1_CD +_NN 
        d_SYM )_) /_NN 2_LS )_) ,_, or_CC recessiveness_NNS (_( 
        a_DT =_SYM 
        b_SYM =_SYM 1_CD and_CC 
        c_SYM =_SYM 
        d_SYM )_) of_IN the_DT resistant_JJ alleles_NNS ._. It_PRP can_MD
        also_RB accommodate_VB overdominance_NN of_IN the_DT resistant_JJ alleles_NNS (_( 
        a_DT >_NN 1_CD ;_: 
        b_SYM >_NN 
        d_SYM ;_: 
        c_SYM >_NN 
        d_SYM )_) ,_, in_IN which_WDT each_DT heterozygote_NN does_VBZ
        better_JJR than_IN either_DT corresponding_JJ homozygote_NN ,_, and_CC
        underdominance_NN ,_, in_IN which_WDT each_DT heterozygote_NN does_VBZ worse_JJR than_IN
        either_DT corresponding_JJ homozygote_NN (_( 
        a_DT <_NN 1_CD ;_: 
        b_SYM <_NN 1_CD ;_: 
        c_SYM <_NN 
        d_SYM )_) ._. In_IN this_DT model_NN ,_, susceptibility_NN
        and_CC resistance_NN are_VBP relative_JJ and_CC simply_RB refer_VBP respectively_RB
        to_TO lower_JJR and_CC higher_JJR probabilities_NNS of_IN favorable_JJ disease_NN
        course_NN ,_, given_VBN infection_NN ._. For_IN simplicity_NN ,_, we_PRP assume_VBP that_IN all_DT
        S_NNP alleles_NNS are_VBP equivalent_NN and_CC all_DT R_NN alleles_NNS are_VBP equivalent_NN ;_:
        our_PRP$ conclusions_NNS could_MD obviously_RB be_VB generalized_JJ to_TO cases_NNS
        where_WRB there_EX is_VBZ a_DT whole_JJ range_NN of_IN effects_NNS for_IN different_JJ
        alleles_NNS ._.
        Under_IN these_DT assumptions_NNS ,_, we_PRP can_MD calculate_VB 
        f_SYM 
        
          hom_NN 
         and_CC 
        f_SYM 
        
          het_NN 
         ,_, the_DT probability_NN of_IN a_DT favorable_JJ disease_NN course_NN for_IN
        homozygotes_NNS (_( the_DT first_NN and_CC fifth_JJ classes_NNS in_IN Table_NNP 1_LS )_) and_CC
        for_IN heterozygotes_NNS (_( the_DT 2_CD nd_NN ,_, 3_CD rd_NN ,_, and_CC 4_CD thclasses_NNS in_IN Table_NNP
        1_LS )_) ._.
        
        The_DT relative_JJ risk_NN (_( RR_NNP )_) of_IN a_DT favorable_JJ outcome_NN for_IN a_DT
        heterozygote_NN compared_VBN to_TO a_DT homozygote_NN is_VBZ defined_VBN as_IN :_:
        
        Population_NN heterozygote_NN advantage_NN corresponds_NNS to_TO RR_NNP >_NN
        1_CD ._. Various_JJ formulations_NNS for_IN relative_JJ risk_NN (_( or_CC odds_NNS ratio_NN ,_,
        used_VBN in_IN case-control_JJ studies_NNS ,_, such_JJ as_IN [_NN 6_CD ]_NN )_) are_VBP used_VBN in_IN
        studies_NNS of_IN HLA_NNP heterozygosity_NN and_CC disease_NN outcome_NN ,_, but_CC in_IN
        all_DT cases_VBZ the_DT cutoff_NN is_VBZ one_CD and_CC a_DT value_NN larger_JJR or_CC smaller_JJR
        than_IN one_CD (_( depending_VBG on_IN the_DT precise_JJ definition_NN used_VBN )_)
        corresponds_NNS to_TO population_NN heterozygote_NN advantage_NN ._. Using_VBG the_DT
        relative_JJ risk_NN equation_NN above_IN ,_, it_PRP can_MD be_VB shown_VBN by_IN taking_VBG
        partial_JJ derivatives_NNS with_IN respect_NN to_TO the_DT parameters_NNS 
        p_NN ,_, Π_NN and_CC Θ_NN ,_, that_IN (_( under_IN the_DT
        assumptions_NNS stated_VBN above_IN )_) the_DT relative_JJ risk_NN increases_NNS with_IN 
        p_NN and_CC Θ_NN and_CC decreases_NNS with_IN Π_NN ._. Thus_RB ,_,
        population_NN heterozygote_NN advantage_NN is_VBZ most_RBS likely_JJ to_TO be_VB
        observed_VBN when_WRB resistant_JJ alleles_NNS are_VBP common_JJ (_( 
        p_NN large_JJ )_) but_CC highly_RB diverse_JJ (_( Π_NN is_VBZ
        small_JJ )_) ,_, and_CC when_WRB susceptible_JJ alleles_NNS are_VBP not_RB diverse_JJ (_( large_JJ
        Θ_NN )_) ._. These_DT trends_NNS can_MD be_VB understood_VBN intuitively_RB ._. Homozygotes_NNP
        will_MD be_VB predominantly_RB resistant_JJ if_IN R_NN alleles_NNS are_VBP common_JJ and_CC
        have_VBP little_JJ diversity_NN and_CC sensitive_JJ when_WRB S_NNP alleles_NNS are_VBP
        common_JJ and_CC have_VBP little_JJ diversity_NN ._. Heterozygotes_NNP will_MD be_VB
        predominantly_RB resistant_JJ if_IN R_NN alleles_NNS are_VBP highly_RB diverse_JJ and_CC
        sensitive_JJ if_IN S_NNP alleles_NNS are_VBP highly_RB diverse_JJ ._.
        Figure_NN 1_CD shows_VBZ the_DT parameter_NN regions_NNS in_IN which_WDT population_NN
        heterozygote_NN advantage_NN is_VBZ expected_VBN and_CC those_DT in_IN which_WDT the_DT
        contrary_NN is_VBZ expected_VBN :_: homozygotes_NNS on_IN average_JJ are_VBP more_RBR
        likely_JJ to_TO have_VB a_DT favorable_JJ disease_NN course_NN ._. Each_DT panel_NN
        reflects_VBZ a_DT different_JJ assumption_NN about_IN the_DT true_JJ genetic_JJ
        basis_NN of_IN resistance_NN -_: assuming_VBG that_IN resistant_JJ alleles_NNS are_VBP
        overdominant_NN ;_: dominant_JJ ;_: additive_JJ ;_: recessive_JJ ;_: or_CC
        underdominant_NN ._. In_IN each_DT case_NN ,_, population_NN heterozygote_NN
        advantage_NN ,_, shown_VBN as_IN the_DT black_JJ region_NN and_CC corresponding_JJ to_TO
        RR_NNP >_NN 1_CD ,_, is_VBZ most_RBS likely_JJ when_WRB resistant_JJ alleles_NNS are_VBP highly_RB
        diverse_JJ and_CC susceptible_JJ alleles_NNS have_VBP low_JJ diversity_NN (_( bottom_JJ
        right_NN of_IN each_DT panel_NN )_) ._.
        Figure_NN 1_CD shows_VBZ that_IN allele-specific_JJ overdominance_NN (_( the_DT
        biological_JJ phenomenon_NN of_IN interest_NN )_) and_CC population_NN
        heterozygote_NN advantage_NN (_( the_DT finding_NN of_IN epidemiological_JJ
        studies_NNS such_JJ as_IN those_DT cited_VBN above_IN )_) are_VBP two_CD different_JJ
        things_NNS ._. Population_NN heterozygote_NN advantage_NN (_( black_JJ )_) may_MD be_VB
        observed_VBN even_RB when_WRB resistance_NN is_VBZ not_RB overdominant_NN ,_, but_CC only_RB
        dominant_JJ ,_, additive_JJ ,_, recessive_JJ or_CC only_RB underdominant_NN ,_, as_RB
        long_RB as_IN allele_NN frequencies_NNS are_VBP sufficiently_RB far_RB toward_IN the_DT
        lower_JJR right_NN of_IN the_DT parameter_NN space_NN (_( high_JJ diversity_NN of_IN
        resistant_JJ alleles_NNS and_CC low_JJ diversity_NN of_IN susceptible_JJ
        alleles_NNS )_) ._. Figure_NN 1_CD shows_VBZ that_IN this_DT is_VBZ possible_JJ under_IN a_DT
        fairly_RB broad_JJ range_NN of_IN parameter_NN combinations_NNS (_( i_NNP ._. e_SYM ._. ,_, there_EX
        are_VBP substantial_JJ black_JJ areas_NNS in_IN the_DT dominant_JJ ,_, additive_JJ and_CC
        recessive_JJ panels_NNS )_) ._.
        The_DT converse_NN is_VBZ also_RB true_JJ ,_, though_IN only_RB in_IN what_WP seem_VBP to_TO
        be_VB very_RB special_JJ circumstances_NNS ._. That_DT is_VBZ ,_, even_RB when_WRB
        allele-specific_JJ overdominance_NN holds_VBZ ,_, it_PRP is_VBZ possible_JJ that_IN
        heterozygotes_NNS on_IN average_JJ will_MD do_VB worse_JJR than_IN homozygotes_NNS ,_, so_RB
        population_NN heterozygote_NN advantage_NN will_MD not_RB be_VB observed_VBN ._.
        This_DT occurs_VBZ with_IN genotype_NN frequencies_NNS sufficiently_RB far_RB
        toward_IN the_DT top_NN left_VBN of_IN Figure_NN 1_CD ,_, with_IN a_DT high_JJ diversity_NN of_IN
        susceptible_JJ alleles_NNS and_CC low_JJ diversity_NN of_IN resistant_JJ ones_NNS ._.
        This_DT occurs_VBZ only_RB rarely_RB for_IN the_DT parameter_NN values_NNS we_PRP have_VBP
        chosen_VBN (_( most_JJS of_IN the_DT leftmost_NN panel_NN is_VBZ black_JJ )_) ,_, and_CC this_DT
        seems_VBZ to_TO be_VB the_DT case_NN for_IN a_DT broad_JJ range_NN of_IN parameter_NN
        values_NNS ._.
        Although_IN neither_DT population_NN heterozygote_NN advantage_NN nor_CC
        allele-specific_JJ overdominance_NN implies_VBZ the_DT other_JJ ,_, the_DT two_CD
        phenomena_NNS are_VBP of_IN course_NN related_VBN ._. Specifically_RB ,_, the_DT
        conditions_NNS to_TO observe_VB population_NN heterozygote_NN advantage_NN are_VBP
        broadest_JJS when_WRB allele-specific_JJ overdominance_NN holds_VBZ and_CC
        become_VB narrower_JJR as_IN the_DT underlying_VBG genetics_NNS becomes_VBZ more_JJR
        "_'' different_JJ "_'' from_IN overdominance_NN of_IN resistance_NN (_( dominance_NN
        -_: >_NN additivity_NN -_: >_NN recessiveness_NNS -_: >_NN
        underdominance_NN )_) ._.
      
      
        Two_CD Examples_NNS
        The_DT intuition_NN behind_IN our_PRP$ result_NN that_DT population_NN
        heterozygote_NN advantage_NN need_MD not_RB reflect_VB allele-specific_JJ
        overdominance_NN can_MD be_VB seen_VBN in_IN two_CD simple_JJ examples_NNS ._.
        Example_NN 1_CD :_: Suppose_VB that_IN there_EX are_VBP two_CD alleles_NNS ,_, each_DT at_IN
        50_CD %_NN frequency_NN in_IN the_DT population_NN ,_, one_CD (_( R_NN )_) conferring_VBG
        resistance_NN and_CC one_CD (_( S_NNP )_) conferring_VBG susceptibility_NN in_IN the_DT
        homozygous_JJ state_NN ._. Population_NN heterozygote_NN advantage_NN will_MD be_VB
        observed_VBN if_IN the_DT probability_NN of_IN a_DT favorable_JJ outcome_NN for_IN
        heterozygotes_NNS is_VBZ greater_JJR than_IN the_DT arithmetic_NN mean_NN of_IN the_DT
        probabilities_NNS of_IN favorable_JJ outcomes_NNS for_IN RR_NNP homozygotes_NNS and_CC
        for_IN SS_NNP homozygotes_NNS ._. In_IN this_DT situation_NN ,_, population_NN
        heterozygote_NN advantage_NN does_VBZ not_RB require_VB overdominance_NN ,_, but_CC
        merely_RB allele_NN effects_NNS that_WDT are_VBP more_JJR than_IN additive_JJ (_( partial_JJ
        dominance_NN )_) ._. Dominance_NNP of_IN particular_JJ HLA_NNP alleles_NNS conferring_VBG
        resistance_NN ,_, and_CC /_NN or_CC recessiveness_NNS of_IN susceptibility_NN (_( poor_JJ
        outcome_NN )_) alleles_NNS ,_, have_VBP been_VBN documented_VBN for_IN schistosomiasis_NNS
        [_NN 24_CD ]_NN ,_, leprosy_NN [_NN 25_CD ]_NN ,_, acute_JJ lymphoblastic_JJ leukemia_NN (_( for_IN
        which_WDT an_DT infectious_JJ cause_NN is_VBZ hypothesized_VBN )_) [_NN 26_CD ]_NN ,_, and_CC
        hepatitis_NNP B_NNP (_( in_IN this_DT case_NN the_DT outcome_NN was_VBD vaccine_NN
        responsiveness_NNS )_) [_NN 27_CD ]_NN ._.
        When_WRB allele_NN frequencies_NNS are_VBP equal_JJ ,_, as_IN in_IN Example_NN 1_CD ,_,
        partial_JJ dominance_NN is_VBZ sufficient_JJ to_TO create_VB population_NN
        heterozygote_NN advantage_NN [_NN 10_CD 11_CD ]_NN ._. When_WRB allele_NN frequencies_NNS
        differ_VBP ,_, the_DT conditions_NNS for_IN population_NN heterozygote_NN
        advantage_NN may_MD become_VB broader_JJR or_CC narrower_JJR ._. This_DT can_MD be_VB seen_VBN
        in_IN a_DT second_NN deliberately_RB extreme_JJ example_NN ._.
        Example_NN 2_CD :_: Suppose_VB there_EX are_VBP 10_CD alleles_NNS ,_, each_DT with_IN
        frequency_NN 5_CD %_NN ,_, each_DT conferring_VBG resistance_NN to_TO a_DT particular_JJ
        disease_NN ,_, and_CC one_CD allele_NN ,_, with_IN frequency_NN 50_CD %_NN ,_, conferring_VBG
        susceptibility_NN ._. In_IN the_DT notation_NN of_IN Table_NNP 1_CD ,_, this_DT
        corresponds_NNS to_TO 
        p_NN =_SYM 
        q_NN =_SYM 0_CD ._. 5_CD ;_: Π_NN =_SYM (_( 10_CD )_) (_( ._. 05_CD )_) 2_CD =_SYM 0_CD ._. 025_CD ;_: Θ_NN =_SYM
        0_CD ._. 25_CD ._. In_IN this_DT case_NN ,_, >_NN 90_CD %_NN of_IN homozygotes_NNS in_IN the_DT
        population_NN will_MD be_VB homozygous_JJ for_IN a_DT susceptible_JJ allele_NN ,_,
        since_IN the_DT frequency_NN of_IN SS_NNP homozygotes_NNS is_VBZ Θ_NN =_SYM 0_CD ._. 25_CD ,_, while_IN
        the_DT frequency_NN of_IN RR_NNP homozygotes_NNS is_VBZ Π_NN =_SYM 0_CD ._. 025_CD ._. In_IN contrast_NN ,_,
        100_CD %_NN of_IN heterozygotes_NNS will_MD have_VB at_IN least_JJS one_CD resistant_JJ
        allele_NN ._. In_IN epidemiological_JJ terms_NNS ,_, this_DT is_VBZ a_DT form_NN of_IN
        confounding_VBG ,_, in_IN which_WDT possession_NN of_IN a_DT resistant_JJ allele_NN is_VBZ
        positively_RB associated_VBN with_IN heterozygosity_NN (_( the_DT exposure_NN of_IN
        interest_NN )_) and_CC positively_RB associated_VBN with_IN having_VBG a_DT favorable_JJ
        disease_NN course_NN (_( the_DT outcome_NN of_IN interest_NN )_) ._. Because_IN of_IN this_DT
        confounding_VBG ,_, under_IN some_DT parameter_NN values_NNS ,_, population_NN
        heterozygote_NN advantage_NN can_MD occur_VB even_RB when_WRB heterozygotes_NNS
        are_VBP not_RB at_IN an_DT advantage_NN relative_JJ to_TO their_PRP$ corresponding_JJ
        homozygotes_NNS ._. Specifically_RB ,_, population_NN heterozygote_NN
        advantage_NN may_MD be_VB observed_VBN when_WRB resistance_NN is_VBZ additive_JJ
        (_( heterozygotes_NNS have_VBP risks_NNS equal_JJ to_TO the_DT average_NN of_IN the_DT risks_NNS
        of_IN the_DT corresponding_JJ homozygotes_NNS )_) ,_, when_WRB resistance_NN is_VBZ
        recessive_JJ ,_, or_CC even_RB when_WRB it_PRP is_VBZ underdominant_NN (_( heterozygotes_NNS
        have_VBP higher_JJR risk_NN of_IN disease_NN than_IN either_DT corresponding_JJ
        homozygote_NN )_) ._.
        Continuing_VBG this_DT example_NN ,_, suppose_VBP that_IN the_DT resistant_JJ
        alleles_NNS are_VBP recessive_JJ to_TO the_DT susceptible_JJ one_CD ,_, so_IN that_IN
        individuals_NNS with_IN one_CD or_CC two_CD copies_NNS of_IN the_DT susceptible_JJ
        allele_NN have_VBP favorable_JJ outcomes_NNS with_IN probability_NN ._. 3_CD and_CC
        individuals_NNS with_IN two_CD resistant_JJ alleles_NNS have_VBP favorable_JJ
        outcomes_NNS with_IN probability_NN ._. 7_CD ;_: these_DT assumptions_NNS correspond_VB
        to_TO 
        x_SYM =_SYM 0_CD ._. 3_CD ;_: 
        a_DT =_SYM 
        b_SYM =_SYM 1_CD ;_: 
        c_SYM =_SYM 
        d_SYM =_SYM 2_CD ._. 33_CD ._. In_IN this_DT example_NN ,_, there_EX are_VBP
        no_DT SS_NNP heterozygotes_NNS since_IN there_EX is_VBZ only_RB one_CD S_NNP allele_NN ;_: SR_NNP
        heterozygotes_NNS make_VBP up_RB 50_CD %_NN of_IN the_DT population_NN (_( 2_CD 
        pq_NN =_SYM 0_CD ._. 5_LS )_) ,_, while_IN RR_NNP heterozygotes_NNS
        (_( carrying_VBG two_CD different_JJ R_NN alleles_NNS )_) make_VB up_RB 
        p_NN 2_CD -_: Π_NN =_SYM 0_CD ._. 225_CD =_SYM 22_CD ._. 5_LS %_NN of_IN the_DT
        population_NN ._. The_DT probability_NN of_IN a_DT favorable_JJ outcome_NN for_IN
        heterozygotes_NNS will_MD be_VB the_DT weighted_JJ average_NN of_IN the_DT
        probabilities_NNS of_IN a_DT favorable_JJ outcome_NN for_IN SR_NNP and_CC RR_NNP
        heterozygotes_NNS (_( using_VBG equation_NN 1_LS )_) :_:
        
        For_IN homozygotes_NNS (_( using_VBG equation_NN 2_LS )_) ,_, the_DT probability_NN of_IN a_DT
        favorable_JJ outcome_NN 
        f_SYM 
        
          hom_NN 
         will_MD be_VB the_DT weighted_JJ average_NN of_IN the_DT probabilities_NNS for_IN
        SS_NNP homozygotes_NNS (_( 25_CD %_NN of_IN the_DT population_NN )_) and_CC for_IN RR_NNP
        homozygotes_NNS (_( 2_CD ._. 5_LS %_NN of_IN the_DT population_NN )_) :_:
        
        Thus_RB ,_, heterozygotes_NNS on_IN average_NN will_MD be_VB 1_CD ._. 26_CD times_NNS more_RBR
        likely_JJ to_TO have_VB a_DT favorable_JJ outcome_NN ,_, even_RB though_IN each_DT
        heterozygote_NN has_VBZ the_DT same_JJ outcome_NN as_IN if_IN s_VBZ /_NN he_PRP were_VBD
        homozygous_JJ for_IN the_DT worse_JJR of_IN the_DT two_CD alleles_NNS s_VBZ /_NN he_PRP carries_VBZ ._.
        In_IN epidemiological_JJ terms_NNS ,_, heterozygotes_NNS would_MD have_VB a_DT
        relative_JJ risk_NN of_IN 0_CD ._. 87_CD of_IN an_DT unfavorable_JJ outcome_NN compared_VBN to_TO
        homozygotes_NNS ._.
        Both_DT of_IN these_DT examples_NNS were_VBD chosen_VBN for_IN the_DT purposes_NNS of_IN
        clarity_NN ,_, rather_RB than_IN for_IN precise_JJ reflection_NN of_IN the_DT allele_NN
        frequencies_NNS in_IN real_JJ populations_NNS ;_: in_IN particular_JJ ,_, few_JJ if_IN any_DT
        populations_NNS have_VBP a_DT single_JJ HLA_NNP allele_NN with_IN a_DT frequency_NN of_IN
        50_CD %_NN ._. Moreover_RB ,_, we_PRP have_VBP simplified_VBN the_DT effects_NNS of_IN alleles_NNS
        into_IN two_CD categories_NNS ,_, resistant_JJ and_CC susceptible_JJ (_( R_NN and_CC S_NNP )_) ,_,
        which_WDT are_VBP simply_RB relative_JJ notions_NNS ._. In_IN fact_NN ,_, real_JJ alleles_NNS
        will_MD likely_JJ have_VB a_DT spectrum_NN of_IN effects_NNS ,_, ranging_VBG from_IN highly_RB
        resistant_JJ ,_, to_TO highly_RB susceptible_JJ ,_, with_IN some_DT alleles_NNS having_VBG
        "_'' no_DT effect_NN ._. "_'' Note_VB ,_, however_RB ,_, that_IN "_'' no_DT effect_NN "_'' is_VBZ also_RB a_DT
        relative_JJ term_NN ,_, and_CC refers_VBZ to_TO an_DT allele_NN whose_WP$ effect_NN on_IN
        disease_NN outcome_NN is_VBZ close_JJ to_TO the_DT population_NN average_NN ._.
      
      
        Discussion_NNP
        The_DT foregoing_VBG examples_NNS show_VBP that_IN the_DT finding_NN of_IN
        population_NN heterozygote_NN advantage_NN ,_, as_IN in_IN the_DT infectious_JJ
        disease_NN studies_NNS cited_VBD ,_, does_VBZ not_RB support_VB an_DT inference_NN of_IN
        allele-specific_JJ overdominance_NN ,_, the_DT condition_NN of_IN primary_JJ
        interest_NN as_IN an_DT immunological_JJ hypothesis_NNS and_CC a_DT mechanism_NN for_IN
        the_DT maintenance_NN of_IN MHC_NNP diversity_NN ._. Put_VB another_DT way_NN ,_,
        population_NN heterozygote_NN advantage_NN may_MD appear_VB due_JJ to_TO a_DT
        combination_NN of_IN the_DT two_CD distinct_JJ mechanisms_NNS we_PRP defined_VBD in_IN
        the_DT Introduction_NNP :_: the_DT protective_JJ or_CC detrimental_JJ effects_NNS of_IN
        particular_JJ alleles_NNS (_( R_NN and_CC S_NNP alleles_NNS in_IN our_PRP$ model_NN )_) ,_, and_CC the_DT
        effects_NNS of_IN heterozygosity_NN itself_PRP ._. The_DT effects_NNS of_IN R_NN and_CC S_NNP
        alleles_NNS appear_VBP as_IN effects_NNS of_IN heterozygosity_NN vs_NNS ._.
        homozygosity_NN because_IN heterozygotes_NNS and_CC homozygotes_NNS will_MD in_IN
        general_JJ carry_VB different_JJ distributions_NNS of_IN S_NNP and_CC R_NN alleles_NNS ;_:
        thus_RB ,_, in_IN an_DT analysis_NN that_WDT fails_VBZ to_TO condition_NN on_IN the_DT alleles_NNS
        carried_VBD ,_, heterozygosity_NN is_VBZ confounded_JJ with_IN the_DT alleles_NNS
        carried_VBD ._.
        One_CD advantage_NN of_IN correctly_RB separating_VBG the_DT effects_NNS of_IN
        individual_JJ alleles_NNS from_IN the_DT effects_NNS of_IN heterozygosity_NN
        conditional_JJ on_IN those_DT alleles_NNS ,_, is_VBZ that_IN each_DT of_IN these_DT
        measures_NNS is_VBZ a_DT characteristic_NN of_IN an_DT individual_NN ,_, rather_RB than_IN
        a_DT population_NN ._. For_IN example_NN ,_, if_IN genotypes_NNS XX_NNP ,_, XY_NNP and_CC YY_NNP have_VBP
        relative_JJ risks_NNS 0_CD ._. 6_CD ,_, 2_CD ._. 1_CD ,_, and_CC 1_CD for_IN clearance_NN of_IN a_DT viral_JJ
        infection_NN ,_, then_RB this_DT should_MD hold_VB true_JJ regardless_RB of_IN who_WP
        else_RB is_VBZ in_IN the_DT population_NN ._. In_IN contrast_NN ,_, we_PRP have_VBP shown_VBN that_DT
        population_NN heterozygote_NN advantage_NN depends_VBZ on_IN not_RB only_RB the_DT
        effects_NNS of_IN individual_JJ genotypes_NNS on_IN disease_NN outcome_NN ,_, but_CC
        also_RB on_IN allele_NN frequencies_NNS ._. Therefore_RB ,_, even_RB if_IN biological_JJ
        and_CC epidemiologic_JJ mechanisms_NNS were_VBD identical_JJ in_IN two_CD
        populations_NNS ,_, but_CC allele_NN frequencies_NNS differed_VBD in_IN those_DT two_CD
        populations_NNS ,_, it_PRP would_MD be_VB perfectly_RB reasonable_JJ to_TO find_VB
        population_NN heterozygote_NN advantage_NN in_IN one_CD but_CC not_RB the_DT
        other_JJ ._.
        The_DT problem_NN we_PRP have_VBP described_VBN with_IN measuring_VBG population_NN
        heterozygote_NN advantage_NN is_VBZ not_RB in_IN principle_NN limited_VBN to_TO
        susceptibility_NN /_NN resistance_NN studies_NNS of_IN 
        infectious_JJ diseases_NNS ._. In_IN principle_NN ,_,
        the_DT same_JJ problem_NN could_MD occur_VB in_IN any_DT study_NN of_IN HLA_NNP
        associations_NNS with_IN disease_NN outcome_NN ._. Interestingly_RB ,_, however_RB ,_,
        in_IN our_PRP$ review_NN of_IN the_DT literature_NN on_IN HLA-chronic_NNP disease_NN
        associations_NNS ,_, we_PRP have_VBP found_VBN no_DT examples_NNS of_IN the_DT problem_NN ._.
        Moreover_RB ,_, direct_JJ estimates_NNS of_IN the_DT allele-specific_JJ effects_NNS
        of_IN heterozygosity_NN (_( relative_JJ to_TO the_DT corresponding_JJ
        homozygotes_NNS )_) ,_, nearly_RB absent_JJ in_IN the_DT infectious_JJ disease-_NN HLA_NNP
        literature_NN ,_, are_VBP frequently_RB found_VBN in_IN studies_NNS of_IN HLA_NNP genotype_NN
        and_CC chronic_JJ (_( mostly_RB autoimmune_JJ )_) diseases_NNS [_NN 28_CD 29_CD 30_CD ]_NN ._. We_PRP
        do_VBP not_RB know_VB the_DT reason_NN for_IN this_DT difference_NN in_IN approach_NN ,_, but_CC
        suspect_VBP that_IN some_DT infectious_JJ disease_NN investigators_NNS ,_,
        informed_VBN by_IN the_DT evolutionary_JJ hypothesis_NNS of_IN overdominance_NN
        for_IN infectious_JJ disease_NN resistance_NN and_CC by_IN animal_NN studies_NNS ,_,
        may_MD have_VB a_DT special_JJ interest_NN in_IN detecting_VBG effects_NNS of_IN
        heterozygosity_NN 
        per_IN se_FW ._. Many_JJ studies_NNS of_IN
        HLA-autoimmune_NNP disease_NN associations_NNS ,_, on_IN the_DT other_JJ hand_NN ,_,
        seem_VBP to_TO focus_VB more_RBR on_IN the_DT effects_NNS of_IN individual_JJ alleles_NNS
        and_CC ,_, having_VBG established_VBD these_DT ,_, move_NN on_IN to_TO investigate_VB the_DT
        dependence_NN of_IN these_DT effects_NNS on_IN genetic_JJ modifiers_NNS ,_, including_VBG
        the_DT identity_NN of_IN the_DT individual_NN 's_POS other_JJ allele_NN at_IN the_DT same_JJ
        locus_JJ ._.
        We_PRP have_VBP shown_VBN that_IN when_WRB allele-specific_JJ overdominance_NN
        exists_VBZ ,_, it_PRP will_MD often_RB be_VB manifest_JJ as_IN population_NN
        heterozygote_NN advantage_NN ,_, but_CC that_IN a_DT finding_NN of_IN population_NN
        heterozygote_NN advantage_NN may_MD be_VB consistent_JJ with_IN other_JJ
        patterns_NNS of_IN allele-specific_JJ effects_NNS ;_: for_IN example_NN ,_, when_WRB
        resistant_JJ and_CC susceptible_JJ alleles_NNS are_VBP equally_RB common_JJ and_CC
        equally_RB diverse_JJ ,_, population_NN heterozygote_NN advantage_NN will_MD
        occur_VB if_IN allele-specific_JJ effects_NNS are_VBP additive_JJ ,_, dominant_JJ or_CC
        overdominant_NN ._. It_PRP is_VBZ difficult_JJ to_TO generalize_VB ,_, without_IN doing_VBG
        a_DT specific_JJ epidemiologic_JJ study_NN ,_, about_IN how_WRB the_DT prevalence_NN
        and_CC diversity_NN of_IN R_NN and_CC S_NNP alleles_NNS would_MD be_VB likely_JJ to_TO occur_VB
        in_IN a_DT given_VBN population_NN ._. O_NNP '_POS Brien_NNP et_CC al_NN ._. [_NN 12_CD ]_NN found_VBD a_DT
        spectrum_NN of_IN estimated_VBN effects_NNS of_IN Class_NNP I_PRP HLA_NNP alleles_NNS on_IN
        HIV-_NNP 1_CD disease_NN progression_NN ,_, and_CC this_DT spectrum_NN seems_VBZ visually_RB
        to_TO be_VB roughly_RB symmetric_JJ ,_, but_CC further_JJ information_NN would_MD be_VB
        required_VBN to_TO determine_VB plausible_JJ values_NNS of_IN 
        p_NN ,_, Θ_NN or_CC Π_NN from_IN these_DT data_NNS ._. One_PRP might_MD
        expect_VB the_DT distribution_NN to_TO be_VB skewed_VBN toward_IN resistant_JJ
        alleles_NNS for_IN diseases_NNS that_WDT have_VBP exerted_VBN long-term_JJ selection_NN
        on_IN a_DT population_NN ,_, but_CC it_PRP is_VBZ difficult_JJ to_TO make_VB confident_JJ
        predictions_NNS about_IN such_JJ patterns_NNS without_IN detailed_JJ knowledge_NN
        of_IN host-pathogen_JJ coevolution_NN ._.
        Our_PRP$ results_NNS do_VBP not_RB deny_VB that_IN allele-specific_JJ
        overdominance_NN at_IN HLA_NNP exists_VBZ in_IN human_JJ populations_NNS with_IN
        respect_NN to_TO infectious_JJ disease_NN resistance_NN ,_, but_CC simply_RB raise_VB
        doubts_NNS about_IN the_DT reliability_NN of_IN the_DT major_JJ evidence_NN that_WDT has_VBZ
        been_VBN adduced_JJ in_IN support_NN of_IN this_DT phenomenon_NN ._. Existing_JJ data_NNS
        suggest_VBP that_IN allele-specific_JJ overdominance_NN may_MD exist_VB in_IN
        some_DT animal_NN infectious_JJ diseases_NNS ,_, but_CC also_RB that_IN simple_JJ
        dominance_NN and_CC other_JJ outcomes_NNS are_VBP commonly_RB observed_VBN [_NN 11_CD ]_NN ._.
        Several_JJ experimental_JJ studies_NNS have_VBP examined_VBN this_DT question_NN
        using_VBG single-strain_JJ infections_NNS in_IN animals_NNS ,_, and_CC while_IN
        suggestions_NNS of_IN allele-specific_JJ overdominance_NN have_VBP been_VBN
        made_VBN ,_, none_NN of_IN the_DT studies_NNS has_VBZ been_VBN entirely_RB convincing_JJ ._.
        Doherty_NNP and_CC Zinkernagel_NNP [_NN 20_CD ]_NN demonstrated_VBD using_VBG congenic_JJ
        mice_NNS that_IN MHC_NNP homozygotes_NNS had_VBD more_RBR vigorous_JJ immune_JJ
        responses_NNS to_TO lymphocytic_JJ choriomeningitis_NNS virus_NN (_( LCMV_NNP )_) than_IN
        the_DT corresponding_JJ homozygotes_NNS ,_, but_CC since_IN the_DT pathology_NN of_IN
        the_DT infection_NN they_PRP used_VBD is_VBZ due_JJ to_TO the_DT immune_JJ response_NN ,_, the_DT
        enhanced_VBN immune_JJ response_NN actually_RB resulted_VBD in_IN reduced_VBN
        survival_NN ._. A_DT study_NN in_IN mice_NNS of_IN resistance_NN to_TO 
        Toxoplasma_NNP gondii_NN showed_VBD that_DT F_NN 
        1_CD offspring_NN of_IN two_CD genetically_RB divergent_JJ
        parent_NN strains_NNS were_VBD more_RBR resistant_JJ than_IN either_DT parent_NN
        strain_NN ,_, but_CC there_EX seems_VBZ to_TO be_VB no_DT demonstration_NN that_DT
        heterozygosity_NN at_IN an_DT MHC_NNP locus_JJ is_VBZ responsible_JJ [_NN 18_CD ]_NN ,_,
        while_IN another_DT reference_NN [_NN 19_CD ]_NN that_WDT has_VBZ been_VBN cited_VBN [_NN 10_CD ]_NN
        as_IN showing_VBG overdominance_NN at_IN MHC_NNP in_IN the_DT same_JJ host-pathogen_JJ
        system_NN does_VBZ not_RB appear_VB to_TO address_VB the_DT question_NN directly_RB ._. A_DT
        study_NN of_IN Marek_NNP 's_POS disease_NN virus_NN in_IN chickens_NNS seems_VBZ to_TO
        demonstrate_VB allele-specific_JJ overdominance_NN at_IN the_DT MHC_NNP using_VBG
        defined_VBN genetic_JJ backgrounds_NNS ,_, but_CC the_DT report_NN does_VBZ not_RB
        clearly_RB specify_VB how_WRB homogeneous_JJ the_DT genetic_JJ background_NN was_VBD
        in_IN these_DT experiments_NNS [_NN 21_CD ]_NN ._.
        From_IN the_DT perspective_NN of_IN the_DT population_NN genetics_NNS debate_NN
        concerning_VBG the_DT role_NN of_IN overdominance_NN in_IN maintaining_VBG
        polymorphism_NN at_IN the_DT MHC_NNP ,_, we_PRP should_MD note_VB that_IN this_DT mechanism_NN
        requires_VBZ allele-specific_JJ overdominance_NN for_IN total_JJ fitness_NN ,_,
        not_RB for_IN resistance_NN to_TO individual_JJ diseases_NNS ._. As_IN noted_VBN by_IN
        Doherty_NNP and_CC Zinkernagel_NNP [_NN 4_CD ]_NN ,_, simple_JJ dominance_NN for_IN
        resistance_NN to_TO each_DT of_IN several_JJ diseases_NNS can_MD create_VB
        allele-specific_JJ overdominance_NN for_IN total_JJ fitness_NN ,_, if_IN
        different_JJ alleles_NNS confer_VBP resistance_NN to_TO different_JJ diseases_NNS [_NN
        10_CD 31_CD ]_NN ._. For_IN these_DT reasons_NNS ,_, our_PRP$ results_NNS ,_, while_IN relevant_JJ to_TO
        the_DT longstanding_JJ debate_NN over_IN the_DT relative_JJ importance_NN of_IN
        various_JJ kinds_NNS of_IN balancing_VBG selection_NN in_IN maintaining_VBG MHC_NNP
        diversity_NN [_NN 32_CD ]_NN ,_, raise_VB doubts_NNS about_IN only_RB one_CD of_IN several_JJ
        lines_NNS of_IN evidence_NN for_IN the_DT overdominance_NN hypothesis_NNS ._.
        Simple_NN and_CC accurate_JJ methods_NNS exist_VBP to_TO determine_VB for_IN a_DT
        single_JJ pair_NN of_IN alleles_NNS how_WRB the_DT three_CD possible_JJ genotypes_NNS (_( 2_CD
        homozygotes_NNS and_CC one_CD heterozygote_NN )_) affect_VB disease_NN outcome_NN ,_,
        and_CC these_DT methods_NNS have_VBP been_VBN used_VBN frequently_RB in_IN the_DT
        literature_NN on_IN autoimmunity_NN and_CC HLA_NNP [_NN 28_CD 29_CD 30_CD ]_NN and_CC once_RB
        (_( to_TO our_PRP$ knowledge_NN )_) in_IN the_DT HLA-infectious_NNP disease_NN literature_NN
        [_NN 33_CD ]_NN ._. It_PRP is_VBZ of_IN additional_JJ interest_NN for_IN epidemiologists_NNS ,_,
        immunologists_NNS ,_, vaccine_NN designers_NNS and_CC evaluators_NNS ,_, and_CC
        population_NN geneticists_NNS to_TO know_VB whether_IN HLA_NNP heterozygosity_NN
        in_IN general_JJ improves_VBZ the_DT immune_JJ response_NN to_TO and_CC outcome_NN of_IN
        infectious_JJ diseases_NNS ._. To_TO answer_VB this_DT question_NN in_IN a_DT
        meaningful_JJ way_NN ,_, it_PRP will_MD be_VB necessary_JJ to_TO develop_VB improved_VBN
        methods_NNS that_WDT estimate_NN the_DT effect_NN of_IN heterozygosity_NN while_IN
        conditioning_NN on_IN the_DT alleles_NNS involved_VBN ._. Meanwhile_RB ,_, findings_NNS
        of_IN population_NN heterozygote_NN advantage_NN should_MD not_RB be_VB
        interpreted_VBN as_IN confirming_VBG the_DT mechanism_NN of_IN allele-specific_JJ
        overdominance_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        The_DT methodological_JJ principles_NNS in_IN this_DT report_NN grew_VBD out_IN of_IN
        discussions_NNS held_VBN by_IN the_DT three_CD authors_NNS ._. ML_NNP formulated_VBN the_DT
        problem_NN and_CC drafted_VBD the_DT manuscript_NN ,_, which_WDT was_VBD edited_JJ and_CC
        revised_VBN by_IN CB_NNP and_CC RA_NNP ._. All_DT authors_NNS read_VBP and_CC approved_VBD the_DT
        final_JJ manuscript_NN ._.
      
      
        Appendix_NNP
        In_IN this_DT appendix_NN we_PRP prove_VBP that_IN the_DT relative_JJ risk_NN defined_VBN
        in_IN Equation_NNP (_( 3_LS )_) is_VBZ increasing_VBG in_IN p_NN and_CC Θ_NN ,_, and_CC decreasing_VBG in_IN
        Π_NN ._.
        As_IN a_DT preliminary_JJ result_NN that_WDT will_MD be_VB useful_JJ later_RB ,_, note_NN
        that_DT and_CC ._.
        
        
          Proof_NNP that_IN the_DT relative_JJ risk_NN is_VBZ
          increasing_VBG in_IN p_NN 
         ._. We_PRP must_MD show_VB that_IN ._. To_TO do_VB so_RB ,_, we_PRP calculate_VBP :_:
        
        By_IN definition_NN ,_, 
        p_NN and_CC Π_NN +_NN Θ_NN are_VBP each_DT between_IN zero_CD and_CC
        one_CD ,_, and_CC all_DT of_IN the_DT parameters_NNS Π_NN ,_, Θ_NN ,_, 
        a_DT ,_, 
        b_SYM ,_, and_CC 
        c_SYM are_VBP positive_JJ ;_: and_CC by_IN assumption_NN ,_, 
        a_DT ≤_NN 
        b_SYM ≤_NN 
        c_SYM ._. Therefore_RB ;_: therefore_RB ,_, all_DT terms_NNS
        in_IN the_DT partial_JJ derivative_JJ are_VBP positive_JJ ,_, so_IN the_DT relative_JJ
        risk_NN is_VBZ increasing_VBG in_IN 
        p_NN ._. QED_NNP ._.
        
        
          Proof_NNP that_IN relative_JJ risk_NN is_VBZ decreasing_VBG
          in_IN Π_NN 
         ._. Since_IN 
        RR_NNP =_SYM 
        f_SYM 
        
          het_NN 
         /_NN 
        f_SYM 
        
          hom_NN 
         ,_, it_PRP is_VBZ sufficient_JJ to_TO show_VB that_IN the_DT numerator_NN ,_, 
        f_SYM 
        
          het_NN 
         ,_, is_VBZ decreasing_VBG in_IN Π_NN and_CC the_DT denominator_NN ,_, 
        f_SYM 
        
          hom_NN 
         ,_, is_VBZ increasing_VBG in_IN Π_NN ._. (_( This_DT is_VBZ intuitively_RB clear_JJ :_: 
        f_SYM 
        
          het_NN 
         is_VBZ the_DT weighted_JJ average_NN of_IN the_DT risk_NN of_IN individuals_NNS in_IN
        the_DT 2_CD nd_NN ,_, 3_CD rd_NN ,_, and_CC 4_CD thcolumns_NNS of_IN Table_NNP 1_CD ;_: increasing_VBG Π_NN
        reduces_VBZ the_DT weight_NN on_IN the_DT highest-risk_JJ category_NN ,_, the_DT 4_CD
        thcolumn_NN with_IN risk_NN 
        cx_NN ,_, thereby_RB reducing_VBG the_DT weighted_JJ
        average_NN ._. Similarly_RB ,_, increasing_VBG Π_NN increases_VBZ the_DT
        representation_NN of_IN RR_NNP homozygotes_NNS among_IN homozygotes_NNS ,_, thereby_RB
        increasing_VBG the_DT average_JJ risk_NN of_IN homozygotes_NNS ._. )_) Formally_RB :_:
        first_JJ ,_, we_PRP show_VBP that_DT 
        f_SYM 
        
          het_NN 
         ,_, is_VBZ decreasing_VBG in_IN Π_NN ,_, namely_RB that_IN ._. Taking_VBG the_DT partial_JJ
        derivative_JJ and_CC rearranging_VBG we_PRP find_VBP :_:
        
        This_DT is_VBZ justified_JJ as_IN follows_VBZ :_: The_DT first_JJ term_NN is_VBZ positive_JJ
        by_IN defnition_NN ._. Inside_IN the_DT curly_JJ brackets_NNS in_IN the_DT penultimate_NN
        line_NN above_IN ,_, we_PRP have_VBP the_DT sum_NN of_IN two_CD terms_NNS ,_, each_DT of_IN which_WDT
        itself_PRP is_VBZ the_DT product_NN of_IN a_DT nonpositive_JJ term_NN and_CC a_DT
        nonnegative_JJ term_NN ;_: thus_RB ,_, the_DT curly_JJ brackets_NNS are_VBP nonpositive_JJ ._.
        Specifically_RB ,_, and_CC are_VBP both_DT nonpositive_JJ because_IN we_PRP assumed_VBD 
        a_DT ≤_NN 
        b_SYM ≤_NN 
        c_SYM ._. [_NN (_( 1_CD -_: 
        p_NN )_) 2_CD -_: Θ_NN ]_NN is_VBZ nonnegative_JJ as_IN noted_VBN at_IN
        the_DT beginning_NN of_IN the_DT appendix_NN ._. The_DT term_NN in_IN curly_JJ brackets_NNS
        is_VBZ nonpositive_JJ ,_, and_CC the_DT term_NN outside_IN is_VBZ positive_JJ ,_, so_IN the_DT
        whole_JJ expression_NN is_VBZ nonpositive_JJ ,_, as_IN stated_VBN ._.
        It_PRP is_VBZ apparent_JJ by_IN inspection_NN that_IN the_DT denominator_NN of_IN the_DT
        relative_JJ risk_NN ,_, 
        f_SYM 
        
          hom_NN 
         ,_, is_VBZ increasing_VBG in_IN Π_NN ._. Since_IN the_DT numerator_NN of_IN the_DT
        relative_JJ risk_NN is_VBZ nonincreasing_VBG in_IN Π_NN ,_, and_CC the_DT denominator_NN of_IN
        the_DT relative_JJ risk_NN is_VBZ increasing_VBG ,_, the_DT relative_JJ risk_NN is_VBZ
        decreasing_VBG in_IN Π_NN ._.
        The_DT argument_NN that_IN the_DT relative_JJ risk_NN is_VBZ increasing_VBG in_IN Θ_NN
        is_VBZ exactly_RB symmetric_JJ to_TO the_DT argument_NN for_IN Π_NN ._.
      
    
  
